Adiponectin secretion enhancer

Patent metadata

Field	Value
Publication number	US-10695360-B2
Application number	US-201815898016-A
Country	US
Kind code	B2
Filing date	Feb 15, 2018
Priority date	Feb 16, 2017
Publication date	Jun 30, 2020
Grant date	Jun 30, 2020

Abstract

The present disclosure provides for the administration of β-NMN, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can be ingested in order to increase the secretion of adiponectin. Also disclosed are methods of treating insulin resistance-related diseases such as of metabolic syndrome, diabetes, hyperlipidemia, fatty liver disease, hypertension, obesity, and arteriosclerosis.

First claim

What is claimed is:

1. A method for enhancing adiponectin secretion, comprising administering to a subject with a disease related to insulin resistance caused by decreased secretion of adiponectin a pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, wherein the disease related to insulin resistance is selected from the group consisting of metabolic syndrome, a fatty liver disease, hypertension, and arteriosclerosis.

2. The method in accordance with claim 1 , wherein the pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof increases adiponectin secretion of adipocytes by 20% or more.

3. The method in accordance with claim 1 , wherein the administering a pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof is orally administering a pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof.

4. The method in accordance with claim 3 , wherein the oral administration comprises adding the β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof to the subject's food or drink.

5. The method in accordance with claim 3 , comprising adding to the subject's drink a powder comprising the pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof.

6. The method in accordance with claim 1 , wherein the subject is a mammal.

7. The method in accordance with claim 6 , wherein the mammal is a human.

8. A method in accordance with claim 1 , wherein the fatty liver disease is selected from the group consisting of alcoholic fatty liver disease and non-alcoholic fatty liver disease.

9. A method in accordance with claim 1 , wherein the pharmaceutically effective amount of β-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof is in a formulation further comprising at least one additional active ingredient.

10. A method in accordance with claim 9 , wherein the at least one additional active ingredient is selected from the group consisting of an adipocyte differentiation promoting substance, a fat accumulation inhibitory substance, a lipolysis promoting substance, and a fat metabolism improving substance.

11. A method in accordance with claim 1 , wherein the method further comprises administering a substance selected from the group consisting of taurine, glutathione, carnitine, creatine, coenzyme Q, glucuronic acid, glucuronolactone, capsicum extract, ginger extract, cacao extract, guarana extract, garcinia extract, theanine, γ-aminobutyric acid, capsaicin, capsiate, various organic acids, flavonoids, polyphenols, catechins, xanthine derivatives, and indigestible oligosaccharides.

12. A method in accordance with claim 1 , wherein the administering comprises administering 0.1 mg to 10 g of β-NMN per day.

Assignees

• Univ Washington
• Oriental Yeast Co Ltd

Inventors

• Yoshino Jun
• Yasuda Hisataka
• Arai Hideo
• ENOMOTO Tetsuro

Classifications

• A61K36/5777

  Theobroma, e.g. cocao or cocoa · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61K31/7004

  Monosaccharides having only carbon, hydrogen and oxygen atoms · CPC title

• A61K36/9068

  Zingiber, e.g. garden ginger · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title